Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-2 of 2 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-2 of 2 studies
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of Ataluren in people with CF who have a nonsense mutation and are not taking aminoglycosides , protocol number PTC124-GD-021-CFThis study evaluated the safety and effectiveness of the drug Ataluren (PTC124®) compared with placebo. This study was for people with CF who have a nonsense mutation and were not receiving chronic inhaled aminoglycosides.
-
Age:
6 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
60 to 90%
-
Number of Visits:
10
-
Length of Participation:
56 weeks
-
-
Restore CFTR ProteinCompleted with Results
Ataluren (PTC 124) in Cystic Fibrosis , protocol number PTC124-GD-009-CFThis trial looked at the effectiveness and safety of ataluren in people with CF who have a nonsense mutation of cystic fibrosis.
-
Age:
6 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
15
-
Length of Participation:
48 weeks
-
Showing 1-2 of 2 studies
- 1
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More